Wuhan Dazhong Dental Med Co (2651) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Wuhan Dazhong Dental Med Co HK$14.66, price HK$28.70, upside -48.9%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Wuhan Dazhong Dental Med Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
15‑month range HK$6.03 – HK$29.48 · fair‑value band HK$11.00 – HK$18.33 · the HK$28.70 price screens above the HK$14.66 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Wuhan Dazhong Dental Med Co in your weekly email
Every Wednesday you see whether Wuhan Dazhong Dental Med Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Wuhan Dazhong Dental Medical Co., Ltd., together with its subsidiaries, operates as a private dental services provider in China.
Show more
Wuhan Dazhong Dental Medical Co., Ltd., together with its subsidiaries, operates as a private dental services provider in China. The company offers oral preventive care, treatment of regular oral diseases, and restorative services; implanting artificial teeth root services; and prevention and treatment of dental and jawbone developmental abnormalities, including misaligned teeth, abnormal occlusion, and irregularities in the size, shape, and position of the jawbone. It also provides beauty repair, pediatric dentistry, periodontal treatment, and comprehensive oral treatment services. Wuhan Dazhong Dental Medical Co., Ltd. was formerly known as Wuhan Dazhong Dental Clinic Co., Ltd. and changed its name to Wuhan Dazhong Dental Medical Co., Ltd. in May 2017. The company was incorporated in 2007 and is headquartered in Wuhan, China. Wuhan Dazhong Dental Medical Co., Ltd. operates as a subsidiary of Hubei Zhongshan Medical Investment Management Co.,Ltd.
Stock analysis
Wuhan Dazhong Dental Med Co (2651) currently trades at HK$28.70, while our model-based Fair Value estimate is HK$14.66, 48.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of HK$24.07 per share, and 4 of the 22 models we run sit above the HK$28.70 price.
Bear case: the Asset-Based group reads lowest at HK$5.08, and 18 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: HK$11.00 (bear) to HK$18.33 (bull), the price of HK$28.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Wuhan Dazhong Dental Med Co reported revenue of 372M CNY in FY2025 versus 22.2M CNY in FY2013, a compound +26.5%/yr. Reported net income was 28.2M CNY in FY2025, compounding +31.6%/yr from FY2013. FY2013 was a trough year, so the rate overstates the trend.
Key figures
Market cap HK$1.4B (≈ $181M) · P/E ratio 26.1 · P/S ratio 1.98 · EPS (TTM) HK$0.4100 · Dividend yield 2.3% · Net margin 7.6% · Return on equity 19.0% · Return on assets (EBIT) 14.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 3% below its 52-week high and 376% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at −49%, 2651 screens richer than that median.
Fair Value models
Bear HK$11.00Fair Value HK$14.66Bull HK$18.33
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.2%
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.5%
’13
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−10.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.3%
Dividend (yield on the price)2.3%
Profit margin 2013 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 18%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +8.7% a year for the price.
Compare Wuhan Dazhong Dental Med Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 250 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside−48.9% · Bottom 25%
Profitability
Return on equity (TTM)19.0% · Top 25%
Return on assets8.3% · Top 25%
Net margin (TTM)7.6% · Above median
Operating margin (TTM)14.0% · Above median
Growth and dividend
Revenue growth−8.3% · Bottom 25%
Dividend yield (TTM)2.3% · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (TTM)26.1× · Pricier than median
P/B3.78× · Priciest 25%
P/S (TTM)3.26× · Priciest 25%
P/FCF15.1× · Pricier than median
EV/EBITDA11.9× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)0· sector 26
PAST (return on equity)76· sector 30
HEALTH (low debt)100· sector 89
DIVIDEND (yield)47· sector 41
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Wuhan Dazhong Dental Med Co Fair Value". https://www.fairvalue-calculator.com/stock/2651
Frequently asked questions
Is Wuhan Dazhong Dental Med Co (2651) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$14.66 versus a price of HK$28.70, about −49% upside (overvalued).
What is the fair value of 2651?
Our model-based fair value for Wuhan Dazhong Dental Med Co is HK$14.66 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$28.70.
What is the quality score of 2651?
Wuhan Dazhong Dental Med Co has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Wuhan Dazhong Dental Med Co (2651)?
Our model-based price target is the fair value of HK$14.66 (as of Sep 27, 2026) from 22 valuation models. Cautious scenario HK$11.00, optimistic scenario HK$18.33. It is a calculation from audited fundamentals, not an analyst target.
What is the Wuhan Dazhong Dental Med Co stock forecast for 2026?
Our models put fair value at HK$14.66, about −49% upside versus a price of HK$28.70 (overvalued). Cautious scenario HK$11.00, optimistic scenario HK$18.33. The calculation is refreshed regularly with new filings.
What is the revenue of Wuhan Dazhong Dental Med Co (2651)?
Wuhan Dazhong Dental Med Co reported trailing-twelve-month revenue of about 372M CNY (latest available figure, as of Sep 27, 2026).
Does Wuhan Dazhong Dental Med Co pay a dividend?
Wuhan Dazhong Dental Med Co currently shows a dividend yield of about 2.33% relative to its recent price (as of Sep 27, 2026).
What growth is priced into Wuhan Dazhong Dental Med Co (2651)?
For today's price to be fair in a discounted-cash-flow model, Wuhan Dazhong Dental Med Co would have to grow free cash flow by +10.6 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 12 years revenue grew +26.5 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 2651 use?
Our models discount Wuhan Dazhong Dental Med Co at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Wuhan Dazhong Dental Med Co that is +10.6 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Wuhan Dazhong Dental Med Co (2651) delivered so far?
Over the past 12 years revenue at Wuhan Dazhong Dental Med Co grew +26.5 % a year. The price currently implies +10.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Wuhan Dazhong Dental Med Co (2651) growing?
The median revenue growth in the sector is +2.0 % a year. That is the yardstick for the growth priced into Wuhan Dazhong Dental Med Co (+10.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Wuhan Dazhong Dental Med Co (2651)?
The free-cash-flow yield on the price is 6.61 %: that much free cash flow Wuhan Dazhong Dental Med Co produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Wuhan Dazhong Dental Med Co (2651)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Wuhan Dazhong Dental Med Co it is HK$14.66 per share (as of Sep 27, 2026), against a price of HK$28.70. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Wuhan Dazhong Dental Med Co stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2651 trades above its calculated fair value: price HK$28.70, fair value HK$14.66, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2651?
No. The price is what the market pays today (HK$28.70); the fair value is what the company's own numbers justify (HK$14.66). For Wuhan Dazhong Dental Med Co the two are HK$14.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is Wuhan Dazhong Dental Med Co worth?
The market values Wuhan Dazhong Dental Med Co at about HK$1.4B (market capitalisation, as of Sep 27, 2026). Per share that is HK$28.70; our models calculate a fair value of HK$14.66 per share.
What do the bullish and bearish scenarios say about 2651?
Our models span a range for Wuhan Dazhong Dental Med Co: cautious scenario HK$11.00, base HK$14.66, optimistic HK$18.33 per share (as of Sep 27, 2026, price HK$28.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2651?
Wuhan Dazhong Dental Med Co trades at a price-to-earnings ratio of 26.1 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$14.66 is built from several models across several years. Other multiples: P/B 3.8, P/S 3.3, EV/EBITDA 11.9.
How solid is the balance sheet of Wuhan Dazhong Dental Med Co (2651)?
Balance-sheet figures for Wuhan Dazhong Dental Med Co (as of Sep 27, 2026): return on equity 19.0%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 2651 from its 52-week high?
Wuhan Dazhong Dental Med Co trades at HK$28.70, about 3% below its 52-week high of HK$29.48 and 376% above the low of HK$6.03 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$14.66 is for.
Which stocks are comparable to Wuhan Dazhong Dental Med Co?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Wuhan Dazhong Dental Med Co stock attractive at the current price?
The data as of Sep 27, 2026: price HK$28.70, calculated fair value HK$14.66 (−49%), Quality Score 65/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2651 calculated?
We run Wuhan Dazhong Dental Med Co through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$14.66, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Wuhan Dazhong Dental Med Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Wuhan Dazhong Dental Med Co (2651)?
The closing price on Sep 30, 2026 was HK$28.70. Our model-based fair value is HK$14.66, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Wuhan Dazhong Dental Med Co right now?
The price sits above even our optimistic bull case (HK$18.33). The favourable scenario is already priced in. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Wuhan Dazhong Dental Med Co
How large is the market capitalisation of Wuhan Dazhong Dental Med Co (2651)?
The market capitalisation of Wuhan Dazhong Dental Med Co is HK$1.4B (≈ $181M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Wuhan Dazhong Dental Med Co (2651)?
The price-to-sales ratio of Wuhan Dazhong Dental Med Co is 1.98 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Wuhan Dazhong Dental Med Co (2651)?
Earnings per share at Wuhan Dazhong Dental Med Co are HK$0.4100 (price ÷ EPS = P/E 26.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Wuhan Dazhong Dental Med Co (2651)?
The dividend yield of Wuhan Dazhong Dental Med Co is 2.3% (payout 163%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Wuhan Dazhong Dental Med Co (2651)?
The net margin of Wuhan Dazhong Dental Med Co is 7.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Wuhan Dazhong Dental Med Co (2651)?
The return on equity (ROE) of Wuhan Dazhong Dental Med Co is 19.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Wuhan Dazhong Dental Med Co (2651)?
On an EBIT basis the return on assets of Wuhan Dazhong Dental Med Co is 14.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Wuhan Dazhong Dental Med Co (2651)?
The operating margin of Wuhan Dazhong Dental Med Co is 14.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Wuhan Dazhong Dental Med Co (2651)?
Revenue at Wuhan Dazhong Dental Med Co is growing −8.3% versus a year earlier (3y avg −3.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Wuhan Dazhong Dental Med Co (2651)?
Earnings per share at Wuhan Dazhong Dental Med Co are growing −46.7% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Wuhan Dazhong Dental Med Co in the live analysis
One click puts Wuhan Dazhong Dental Med Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
